医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Ningbo NewBay Medical Technology Co., Ltd. Announces a License Agreement with Genentech

2020年01月27日 PM11:00
このエントリーをはてなブックマークに追加


 

NINGBO, China

Ningbo NewBay Medical Technology Co., Ltd., a subsidiary of Ningbo Tai Kang Medical Technology Co., Ltd. announced today that it has entered into a licensing agreement with Genentech, a member of the Roche Group, under which it has been granted the exclusive global rights to further develop and commercialize GDC-0570, a small molecule Pan-PIM inhibitor that is active against multiple myeloma and prostate cancer in preclinical models. PIM kinases regulate cell metabolism, growth and survival.

“We are very pleased to enter this global exclusive license agreement with Genentech. We look forward to working with medical experts and global regulatory agents to accelerate clinical development of this promising investigational medicine,” commented Dr. Zhenhai Shen, CEO of Ningbo NewBay Medical Technology Co., Ltd.

Under the agreement, Genentech will receive an upfront payment and will be eligible to receive milestone payments linked to clinical, regulatory and commercial successes, as well as royalty payments.

About GDC-0570

GDC-0570 is a small molecule Pan-PIM inhibitor discovered and developed by Genentech. PIM-1/2/3 are Serine/Threonine kinases which play an essential role in the regulation of signal transduction cascades. GDC-0570 is a potential first-in-class drug candidate.

About Ningbo NewBay Medical Technology Co., Ltd.

Ningbo NewBay Medical Technology Co., Ltd. is an oncology focused biopharma company based in China with global development capabilities. It is a wholly owned subsidiary of Ningbo Tai Kang Medical Technology Co., Ltd. NewBay and Tai Kang own the Greater China right for two EP4 antagonists from AskAt, Inc. and the global right for c-KIT inhibitor from AstraZeneca.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200127005369/en/

CONTACT

Ms. Mingyuan Yuan

myuan@newbaypharma.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • TIENS Group will Become a Global Participant in the Future Massive Health Industry
  • エンヨ・ファーマがB型慢性肝炎患者でVonafexor(EYP001)を検討中の第2a相試験2件から得た16週目のトップライン中間解析結果を発表
  • Dr. Reddy’s Announces the Re-Launch of Over-the-Counter Naproxen Sodium Tablets USP, 220 mg, Store-Brand Equivalent of Aleve® in the U.S. Market
  • WNS Launches PRECIZON to Deliver Cloud-based Competitive Intelligence for Life Sciences Industry
  • Arcturus Announces Approval of Singapore Clinical Trial Application to Advance ARCT-154 and ARCT-165, Next Generation STARR™ mRNA Vaccines Targeting SARS-CoV-2 Variants of Concern, in a Phase 1/2 Study